Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.51    -0.09 (-5.62%)
Bid:
1.51
Ask:
2.06
Spread: 0.55 (36.424%)
Market Cap: £5.30m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Directorate Change

1 Jul 2014 07:00

RNS Number : 9952K
Proteome Sciences PLC
01 July 2014
 



 

 

 

 

 

PRESS RELEASE

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Appointment of Roger McDowell as Non-Executive Director

 

1st July, 2014 Proteome Sciences is pleased to announce the appointment of Roger Steven McDowell to the Board of the Company as a non-executive Director with immediate effect.

 

Roger McDowell has a highly successful career as a businessman and entrepreneur. He was Managing Director of Oliver Ashworth for eighteen years before its sale to St. Gobain. He is currently the Chairman or a non-executive director of seven listed companies, namely Avingtrans plc, Servelec Group plc, Renovo plc, Alkane Energy plc, Swallowfield plc, IS Solutions plc and Augean plc. He brings considerable commercial experience with him and is a keen exponent of growing shareholder value.

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Roger Steven McDowell, age 60 years, is or has been a director of the following companies during the five years preceding the date of this announcement:

 

Current directorships Past directorships

Corsair Techinvest Ltd One Advice Group plc

Fineguard Ltd Ultimate Finance Group plc

Augean plc

Disperse Ltd

Dovehoco 201 Ltd

Avingtrans plc

IS Solutions plc

Swallowfield plc

Alkane Energy plc

Renovo plc

Servelec Group plc

 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies. 

 

At the AGM, held on 30 June 2014, it was announced that Steve Harris, the Chairman, was proposing to retire and he has now formally stepped down as a director.

 

The Board of Proteome Sciences would like to thank him for the considerable contribution and support that he has provided to the Company over the last 20 years, a period in which the Company's outstanding biomarker research has been converted into products, services and commercial revenue. We wish him a long and enjoyable retirement.

 

The CEO, Christopher Pearce, has been appointed Executive Chairman. Dr. Ian Pike remains the Chief Operating Officer.

 

 

- Ends -

 

 

 

 

 

 

For further information please contact:

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Tel: +44 (0)1932 865065

Dr. Ian Pike, Chief Operating Officer

James Malthouse, Finance Director

Nominated Adviser

Cenkos

Stephen Keys/Callum Davidson

Tel: +44 (0)20 7397 8900

Public Relations

IKON Associates

Adrian Shaw

Tel: +44 (0)1483 271291

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAKBLFXZQFEBBD
Date   Source Headline
26th May 20229:04 amRNSChange of Registered Office
16th May 20221:24 pmRNSResult of AGM
16th May 20227:00 amRNSAGM Statement
12th May 20227:00 amRNSSubstantial Contract Win
26th Apr 20224:45 pmRNSDirector/PDMR Shareholding
21st Apr 20225:13 pmRNSDirector/PDMR Shareholding
11th Apr 20227:00 amRNSInvestor Presentation
1st Apr 20226:01 pmRNSDirector shareholding
31st Mar 20227:09 amRNSFinal Results
30th Mar 202211:24 amRNSLoan amendment
29th Mar 20227:00 amRNSNotice of Results
16th Feb 20224:40 pmRNSSecond Price Monitoring Extn
16th Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSTrading Update
31st Dec 202112:36 pmRNSPrice Monitoring Extension
20th Dec 20217:00 amRNSSubstantial Contract Win
9th Dec 20214:41 pmRNSSecond Price Monitoring Extn
9th Dec 20214:36 pmRNSPrice Monitoring Extension
29th Nov 20214:36 pmRNSPrice Monitoring Extension
26th Nov 20214:36 pmRNSPrice Monitoring Extension
5th Nov 20217:00 amRNSPRM,INmune Bio presenting biomarker discovery data
3rd Nov 20214:41 pmRNSSecond Price Monitoring Extn
3rd Nov 20214:36 pmRNSPrice Monitoring Extension
26th Aug 20214:40 pmRNSSecond Price Monitoring Extn
26th Aug 20214:36 pmRNSPrice Monitoring Extension
29th Jul 20217:00 amRNSInterim Results
15th Jul 20214:41 pmRNSSecond Price Monitoring Extn
15th Jul 20214:35 pmRNSPrice Monitoring Extension
18th Jun 20211:14 pmRNSLoan amendment
8th Jun 202112:54 pmRNSGrant of Options and PDMR/director shareholdings
19th May 20216:01 pmRNSIssuance of key TMT Patent
18th May 20219:48 amRNSChange of Registered Office
12th May 20214:36 pmRNSPrice Monitoring Extension
7th May 20214:41 pmRNSSecond Price Monitoring Extn
7th May 20214:36 pmRNSPrice Monitoring Extension
6th May 20214:41 pmRNSSecond Price Monitoring Extn
6th May 20214:35 pmRNSPrice Monitoring Extension
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202111:57 amRNSResult of AGM
5th May 202111:00 amRNSAGM Statement
27th Apr 20214:40 pmRNSSecond Price Monitoring Extn
27th Apr 20214:35 pmRNSPrice Monitoring Extension
19th Apr 20215:25 pmRNSDirector/PDMR Shareholding
14th Apr 202112:18 pmRNSDirector/PDMR Shareholding
7th Apr 20214:40 pmRNSSecond Price Monitoring Extn
7th Apr 20214:35 pmRNSPrice Monitoring Extension
1st Apr 202112:48 pmRNSHolding(s) in Company
1st Apr 20219:34 amRNSInvestor Presentation
1st Apr 20217:40 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.